Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Survival: monthsCountry:Switzerland
Toxiciy Grade:4City/State/Province:Lausanne
Treatments:ChemotherapyHospital:Centre Hospitalier Universitaire Vaudois
Drugs:Journal:Link
Date:Feb 2011

Description:

Patients:
This study involved 37 glioblastoma patients who had previously been treated and had recurrence or progression of their disease. The median patient age was 57 years and 76% were male.

Treatment:
Patients were treated with a chemotherapy agent called sagopilone, also known as ZK-EPO or ZK-219477.

Toxicity
The maximum toxicity level reported was of grade 4, consisting of one case of peripheral neuropathy. Also reported were 3 cases each of grade 3 fatigue and neutropenia.

Results:
The reported median overall survival was 7.6 months.

Support:
This study was supported by Bayer Schering Pharma, makers of sagopilone.

Correspondence: Dr. Roger Stupp; email: [email protected]



Back